Use of ascorbyl glucoside in health food and oral care products

Abstract

This invention provides the application of ascorbate glucoside in health foods and oral care products, belonging to the field of health foods and oral care. The ascorbate glucoside has the configuration 2-O-α-D-glucosyl-L-ascorbic acid (AA2G). AA2G can effectively inhibit α-glucosidase activity and has a high binding rate to bile acids. Animal experiments show that AA2G can significantly reduce blood glucose, serum triglyceride (TG), and serum total cholesterol (TC) concentrations in diabetic model mice, exhibiting auxiliary hypoglycemic and lipid-lowering effects. Furthermore, AA2G also has inhibitory effects on *Streptococcus mutans* and *Porphyromonas gingivalis*, demonstrating anti-caries efficacy. In addition, AA2G sustainably and stably exerts its auxiliary hypoglycemic effect, with its long-term hypoglycemic capacity significantly superior to that of VC and β-configuration ascorbate glucoside (AA-2βG). The application of AA2G in health foods and oral care products can effectively reduce blood glucose and lipids and effectively improve dental caries problems.

Description

Technical Field

[0001] This invention relates to the fields of health food and oral care, specifically to the application of ascorbate glucoside in health food for assisting in lowering blood sugar and lipids, and in oral care products. Background Technology

[0002] As people's living standards improve, high-sugar foods such as milk tea, carbonated drinks, and baked desserts are popular due to their delicious taste. However, excessive sugar intake can have adverse effects on health. High-sugar, high-fat foods and drinks are high in calories, and excessive consumption can easily lead to fat accumulation and obesity. Long-term unhealthy eating habits put a burden on the body, easily leading to symptoms of high blood sugar and high blood lipids. Furthermore, residual carbohydrates in the mouth are easily absorbed by oral planktonic bacteria—Streptococcus mutans—that have already colonized the tooth surface. Streptococcus mutans Porphyromonas gingivalis ferments and produces acid, forming an adhesive plaque layer on the tooth surface. This allows the produced organic acids to remain in contact with the tooth surface for an extended period, causing damage to the hard tissues of the teeth, leading to cavities and affecting oral health. Porphyromonas gingivalis Late-term colonizing bacteria play a dominant role in periodontal disease. Currently, oral antibiotics are the primary treatment for bacterial oral infections both domestically and internationally. However, long-term antibiotic use can disrupt the balance of the oral ecosystem and exacerbate bacterial resistance.

[0003] Commonly available health supplements that help lower blood sugar and blood lipids mainly involve natural products and vitamins. Among them, vitamin C is widely used as a multifunctional ingredient that can be consumed and used in cosmetics. Vitamin C (also known as ascorbic acid, VC) is a vitamin that participates in many physiological activities in the human body. Because the hydroxyl group on C2 is easily affected by pH, metal ions, heat, and light, VC has poor stability. Therefore, various relatively stable derivatives, such as salts, esters, and glycosyl derivatives, have been developed.

[0004] 2-O-α-D-glucosyl-L-ascorbic acid in ascorbate glucoside is also known as AA2G. AA2G is synthesized by modifying the C-2 of the ascorbic acid molecule through chemical and biological methods. The hydroxyl group of the 2,3-endiol in the ascorbic acid molecule is replaced by a glucosyl group linked by an α-1,4-glycosidic bond. This hydroxyl group is the unstable and antioxidant site of ascorbic acid. The introduced glucosyl group plays a masking role. Therefore, AA2G has good stability and antioxidant properties. Specifically, (1) AA2G has strong stability and can resist adverse conditions such as light, oxygen, and heavy metals. It can be absorbed by the human body and can be slowly hydrolyzed and released in the human body to continuously supplement the human body with ascorbic acid. Therefore, it can play a role in food as a stabilizer, ascorbic acid supplement, etc., to improve food quality. (2) AA2G has the effects of promoting collagen synthesis, inhibiting melanin formation, absorbing and resisting ultraviolet rays, making the skin firm and elastic, whitening, and preventing photoaging. Due to its good collagen activity, it is easily absorbed by the skin and is widely used in the cosmetics industry. (3) In animal husbandry, AA2G can promote the growth and development of animals, promote the egg production of breeding chickens, improve the lactation capacity of sows and the sperm motility of breeding pigs, and improve the health of animals. (4) In the pharmaceutical field, the antioxidant effect of AA2G is beneficial to improve human immunity, inhibit viral and bacterial infections, treat infections after injury and surgery, and prevent and treat colds.

[0005] In summary, AA2G exhibits strong stability and plays an important role in whitening, anti-wrinkle, firming, and improving immunity. However, no research has yet been found on its role in assisting in lowering blood sugar, reducing lipids, and oral care.

[0006] As people's living standards improve, high-sugar foods such as milk tea, carbonated drinks, and baked desserts are popular due to their delicious taste. However, excessive sugar intake can have adverse effects on health. High-sugar, high-fat foods and drinks are high in calories, and excessive consumption can easily lead to fat accumulation and obesity. Long-term unhealthy eating habits put a burden on the body, easily leading to symptoms of high blood sugar and high blood lipids. Furthermore, residual carbohydrates in the mouth are easily absorbed by oral planktonic bacteria—Streptococcus mutans—that have already colonized the tooth surface. Streptococcus mutans Porphyromonas gingivalis ferments and produces acid, forming an adhesive plaque layer on the tooth surface. This allows the produced organic acids to remain in contact with the tooth surface for an extended period, causing damage to the hard tissues of the teeth, leading to cavities and affecting oral health. Porphyromonas gingivalis Late-term colonizing bacteria play a dominant role in periodontal disease. Currently, oral antibiotics are the primary treatment for bacterial oral infections both domestically and internationally. However, long-term antibiotic use can disrupt the balance of the oral ecosystem and exacerbate bacterial resistance.

[0007] Commonly available health supplements that help lower blood sugar and blood lipids mainly involve natural products and vitamins. Among them, vitamin C is widely used as a multifunctional ingredient that can be consumed and used in cosmetics. Vitamin C (also known as ascorbic acid, VC) is a vitamin that participates in many physiological activities in the human body. Because the hydroxyl group on C2 is easily affected by pH, metal ions, heat, and light, VC has poor stability. Therefore, various relatively stable derivatives, such as salts, esters, and glycosyl derivatives, have been developed.

[0008] 2-O-α-D-glucosyl-L-ascorbic acid in ascorbate glucoside is also known as AA2G. AA2G is synthesized by modifying the C-2 of the ascorbic acid molecule through chemical and biological methods. The hydroxyl group of the 2,3-endiol in the ascorbic acid molecule is replaced by a glucosyl group linked by an α-1,4-glycosidic bond. This hydroxyl group is the unstable and antioxidant site of ascorbic acid. The introduced glucosyl group plays a masking role. Therefore, AA2G has good stability and antioxidant properties. Specifically, (1) AA2G has strong stability and can resist adverse conditions such as light, oxygen, and heavy metals. It can be absorbed by the human body and can be slowly hydrolyzed and released in the human body to continuously supplement the human body with ascorbic acid. Therefore, it can play a role in food as a stabilizer, ascorbic acid supplement, etc., to improve food quality. (2) AA2G has the effects of promoting collagen synthesis, inhibiting melanin formation, absorbing and resisting ultraviolet rays, making the skin firm and elastic, whitening, and preventing photoaging. Due to its good collagen activity, it is easily absorbed by the skin and is widely used in the cosmetics industry. (3) In animal husbandry, AA2G can promote the growth and development of animals, promote the egg production of breeding chickens, improve the lactation capacity of sows and the sperm motility of breeding pigs, and improve the health of animals. (4) In the pharmaceutical field, the antioxidant effect of AA2G is beneficial to improve human immunity, inhibit viral and bacterial infections, treat infections after injury and surgery, and prevent and treat colds.

[0009] In summary, AA2G exhibits strong stability and plays an important role in whitening, anti-wrinkle, firming, and improving immunity. However, no research has yet been found on its role in assisting in lowering blood sugar, reducing lipids, and oral care. Summary of the Invention

[0010] Given the current research gaps, this invention aims to provide an application of ascorbate glucoside in health foods and oral care products.

[0011] The technical solution adopted in this invention is as follows:

[0012] In a first aspect, the present invention provides the use of ascorbate glucoside in the preparation of health foods for assisting in lowering blood sugar and / or blood lipids, wherein the ascorbate glucoside is 2-O-α-D-glucosyl-L-ascorbic acid.

[0013] Optionally, the health food includes beverages, oral liquids, tablets, powders, jelly gels, capsules, or syrups.

[0014] In a second aspect, the present invention provides a health food for assisting in lowering blood sugar and / or blood lipids, wherein the health food comprises ascorbate glucoside, said ascorbate glucoside being 2-O-α-D-glucosyl-L-ascorbic acid.

[0015] Optionally, the health food product may also include excipients acceptable to health food products.

[0016] A third aspect of the present invention provides the use of ascorbate glucoside in the preparation of oral care products for treating dental caries, wherein the ascorbate glucoside is 2-O-α-D-glucosyl-L-ascorbic acid.

[0017] Optionally, the oral care product includes toothpaste, tooth powder, oral spray, or mouthwash.

[0018] In a fourth aspect, the present invention provides an oral care product for treating dental caries, comprising ascorbate glucoside, wherein the ascorbate glucoside is 2-O-α-D-glucosyl-L-ascorbic acid.

[0019] Optionally, the oral care product may also include excipients acceptable for use in oral care products.

[0020] Beneficial Effects: This invention provides the application of ascorbate glucoside in health foods and oral care products. The ascorbate glucoside has the configuration 2-O-α-D-glucosyl-L-ascorbic acid (AA2G). AA2G can effectively inhibit α-glucosidase activity and has a high binding rate to bile acids. Animal experiments show that AA2G can significantly reduce blood glucose, serum triglyceride (TG), and serum total cholesterol (TC) concentrations in diabetic model mice, exhibiting auxiliary hypoglycemic and lipid-lowering effects. Furthermore, AA2G also has inhibitory effects on Streptococcus mutans and Porphyromonas gingivalis, demonstrating anti-caries efficacy. In addition, AA2G sustainably and stably exerts its auxiliary hypoglycemic effect, and its long-term hypoglycemic capacity is significantly superior to that of VC and β-configuration ascorbate glucoside (AA-2βG). The application of AA2G in health foods and oral care products can effectively reduce blood glucose and lipids and effectively improve dental caries problems. Attached Figure Description

[0021] Figure 1The graph shows the inhibition rate of AA2G on α-glucosidase in Example 1 of this invention.

[0022] Figure 2 This is a graph showing the bile acid binding rate of AA2G in Example 2 of the present invention.

[0023] Figure 3 This is a graph showing the effect of AA2G on blood glucose concentration in mice in Example 3 of the present invention.

[0024] Figure 4 This is a graph showing the effect of AA2G on serum triglycerides (TG) in mice in Example 3 of the present invention.

[0025] Figure 5 This is a graph showing the effect of AA2G on total cholesterol (TC) in mouse serum in Example 3 of the present invention.

[0026] Figure 6 This is a graph showing the effect of AA2G, AA-2βG, and VC on blood glucose concentration at different time points in Example 4 of the present invention.

[0027] Figure 7 This is a graph showing the effects of AA2G, AA-2βG, and VC on serum VC concentrations at different time points in Example 4 of the present invention.

[0028] Figure 8 This is a graph showing the effect of AA2G, AA-2βG and VC on blood glucose concentration after 45 days of administration in Example 4 of the present invention. Detailed Implementation

[0029] This invention provides the application of ascorbate glucoside in health foods and oral care products. To make the objectives, technical solutions, and effects of this invention clearer and more explicit, the invention is further described in detail below. The specific embodiments described herein are merely illustrative of the invention, and the scope of protection is not limited to the content described.

[0030] Ascorbate glucoside can be classified into α-configuration and β-configuration according to different configurations. The configuration involved in this invention is 2-O-α-D-glucosyl-L-ascorbic acid (abbreviated as AA2G), and its chemical structural formula is as follows:

[0031] .

[0032] This invention provides the application of AA2G in health foods and oral care, especially in assisting in lowering blood sugar, lowering blood lipids, and preventing tooth decay.

[0033] When the AA2G described in this invention is used in health food products, it can be in the form of beverages, oral liquids, tablets, granules, jelly gels, capsules, syrups, but is not limited thereto.

[0034] When used in oral care products, the AA2G described in this invention can be in the form of toothpaste, tooth powder, oral spray or mouthwash, but is not limited thereto.

[0035] In other words, the health food and oral care products described in this invention are not limited to the above-mentioned forms. Any product containing AA2G and used to assist in lowering blood sugar, lowering blood lipids, and preventing tooth decay should fall within the scope of protection of this invention.

[0036] The present invention will now be described in detail through specific embodiments.

[0037] Example 1

[0038] α-glucosidase inhibitory activity assay

[0039] Alpha-glucosidase inhibitors are important drugs for the treatment of non-insulin-dependent diabetes mellitus. Therefore, the inhibition rate of α-glucosidase was measured to evaluate the auxiliary hypoglycemic ability of the samples. The experimental design is shown in Table 1, and the formula for calculating the inhibition rate of α-glucosidase is shown in (1):

[0040] α-glucosidase inhibition rate = 1 - (A1 - A2) / (A3 - A4) * 100% ….............(1)

[0041] Table 1. Experimental Design of α-Glucosidase

[0042]

[0043] The results are shown in Table 2 below, and the inhibition rate curves are as follows: Figure 1 As shown:

[0044] Table 2. Inhibition rate of α-glucosidase by the samples

[0045]

[0046] As shown in Table 2, when the concentration of AA2G was 4–40 mg / mL, the inhibition rate of α-glucosidase gradually increased with increasing sample concentration, reaching 6.92%, 15.36%, 18.25%, 31.42%, 47.06%, and 96.38%, respectively, with P values ​​all less than 0.05. This indicates that AA2G exhibits superior auxiliary hypoglycemic ability.

[0047] Example 2

[0048] Determination of bile acid binding capacity

[0049] The biosynthesis of bile acids provides an important pathway for cholesterol metabolism. Binding to bile acids prevents their reabsorption and stimulates the conversion of cholesterol in plasma and liver into bile acids, thus consuming more cholesterol. Therefore, by measuring the binding capacity with bile acids, the effect of the sample in lowering the body's cholesterol levels can be verified, thereby demonstrating its ability to assist in lowering blood lipids.

[0050] An appropriate amount of sample was added to 1 mL of HCl (0.01 mol / L) and digested in a 37 ℃ water bath for 1.5 h. This step simulates the gastric digestion process: the pH of the reaction system was adjusted to 7.0 using 0.1 mol / L NaOH aqueous solution, and 5 mL of trypsin and 4 mL of diluted bile acid solution were added. After reacting in a 37 ℃ water bath for 1 h, the mixture was centrifuged at 10000 r / min for 10 min, and the supernatant was collected to determine the bile acid content using a bile acid kit (TBA) (enzyme cycling method). Cholestyramine was used as the positive control group, and PBS was used as the blank control group instead of the sample.

[0051] The formula for calculating the bile acid binding rate is shown in (2):

[0052] Bile acid binding rate = (Bile acid concentration in blank control group - Bile acid concentration in sample group) / Bile acid concentration in blank control group * 100% …....................... (2)

[0053] The results are shown in Table 3 below, and the binding rate curves are as follows: Figure 2 As shown:

[0054] Table 3. Bile acid binding rate of samples

[0055]

[0056] As shown in Table 3, when the concentration of AA2G was 10–50 mg / mL, the bile acid binding rate gradually increased with increasing sample concentration, reaching 8.50%, 20.19%, 43.24%, 50.18%, 68.55%, and 86.25%, respectively, with P values ​​all less than 0.05. This indicates that AA2G has an auxiliary effect in lowering blood lipids.

[0057] Example 3

[0058] Effects of the study on blood glucose and blood lipids in experimentally diabetic mice

[0059] A high-sugar, high-fat model was established using SPF-grade adult male Kunming mice (weighing 20-25 g) fed a high-sugar, high-fat diet and intraperitoneal injection of alloxan.

[0060] (1) High sugar and high fat modeling

[0061] Experimental mice were allowed free access to food and water for one week of acclimatization, maintained at a temperature of 20±2 ℃ and a relative humidity of 55%±5%. After one week, the mice were randomly divided into two groups: a control group (≥10 mice) fed with normal feed, and a model group (≥50 mice) fed with a high-sugar, high-fat diet. Both groups were allowed free access to water and food for 8 weeks. After a 24-hour fast with free access to water, the control group was injected with saline, while the model group received an intraperitoneal injection of alloxan solution at a dose of 120 mg / (kg·bw). Three days after modeling, fasting blood glucose levels were measured. Mice with blood glucose levels higher than 20 mmol / L were considered high-sugar, high-fat model mice. Fifty successfully modeled mice were randomly divided into five groups: a high-sugar, high-fat group, three sample groups (high-dose, medium-dose, and low-dose sample groups), and a positive control group, with 10 mice in each group.

[0062] (2) Observation indicators and detection

[0063] During the experiment, the blank control group and the high-sugar, high-fat group were administered physiological saline by gavage. The three sample groups (high-dose, medium-dose, and low-dose) were administered AA2G by gavage at doses of 50, 200, and 300 mg / (kg·bw). The positive control group was administered metformin (100 mg / (kg·bw)) by gavage. All participants had free access to water during the experiment. The blank control group maintained a controlled diet, while the remaining five groups maintained a high-sugar, high-fat diet. The experiment lasted 45 days. After the last administration, the mice were fasted for 12 hours. Blood was collected from the tail after anesthesia, and blood glucose was measured using a glucometer. Serum triglycerides (TG) and total cholesterol (TC) were measured using a kit.

[0064] (3) Results and Analysis

[0065] As shown in Table 4:

[0066] Table 4. Effects of the samples on blood glucose levels in experimental diabetic mice

[0067]

[0068] Note: *: Sample group vs. high-sugar, high-fat group (NC), P<0.05; ∆: M group vs. blank group (BC), P<0.05

[0069] A high-sugar, high-fat mouse model was established using a high-sugar, high-fat diet and intraperitoneal injection of alloxan. Mice in the model group were administered AA2G via gavage. The results are shown in Table 4. The differences in different indicators among the four groups are as follows: Figure 3 , Figure 4 , Figure 5As shown: Compared with the blank group (BC), the high-sugar, high-fat group (M) showed significantly higher concentrations of blood glucose, serum triglycerides (TG), and serum total cholesterol (TC), indicating successful model establishment. The PC group showed significantly lower levels than the M group (P<0.05), indicating the effectiveness of the experiment. The concentrations of the three indicators in the sample group were significantly lower than those in the M group (P<0.05). The blood glucose, TG, and TC levels in the sample group were all significantly lower than those in the M group, indicating that AA2G has the effect of assisting in lowering blood glucose and blood lipids.

[0070] Example 4

[0071] Comparison of the bioactivity of AA2G, AA-2βG and VC in lowering blood sugar

[0072] Experimental diabetic mice treated in the same manner as in Example 3 were used, with four groups: a blank control group (≥10 mice), a high-glucose, high-fat group (≥10 mice), a positive control group (≥10 mice), and a sample group (≥10 mice). The feeding method for each group was the same as in Example 3. The sample group consisted of three subgroups: 55 mg / (kg·bw) of vitamin C, 105 mg / (kg·bw) of AA2G, and 105 mg / (kg·bw) of AA-2βG, for a period of 45 days. Thirty minutes after the first administration, blood samples were taken to measure the vitamin C and blood glucose levels in the three sample groups. No feed was given for the following 8 hours. Subsequently, blood samples were taken at 2 h, 3 h, 5 h, and 8 h to measure the serum vitamin C and blood glucose levels in each group. The positive control group received 100 mg / (kg·bw) of metformin. Blood samples were collected from the blank control group, high-sugar and high-fat group, and positive control group at the same time points as the sample group, and only the blood samples at 8 h were tested and analyzed; after fasting for 12 h after the last administration, blood was collected from the tail after anesthesia, and blood glucose was measured using a blood glucose meter.

[0073] The results of blood glucose concentration changes over time are shown in Table 5, and the curves of blood glucose concentration changes over time are shown in the figure. Figure 6 As shown:

[0074] Table 5. Comparison of blood glucose concentrations of AA2G, AA-2βG, and VC at different time points.

[0075]

[0076] Note: P < 0.05 indicates a significant difference, while P ≥ 0.05 indicates no significant difference.

[0077] The changes in serum vitamin C concentration over time are shown in Table 6, and the curves of vitamin C concentration changes over time are shown in the figure. Figure 7 As shown:

[0078] Table 6. Comparison of serum VC concentrations of AA2G, AA-2βG, and VC at different time points.

[0079]

[0080] Note: P < 0.05 indicates a significant difference, while P ≥ 0.05 indicates no significant difference.

[0081] Mice that had undergone modeling were used as research subjects. Blood glucose concentrations were measured at 0.5, 2, 3, 5, and 8 hours after the first administration of the drug to compare the blood glucose-lowering abilities among the sample groups.

[0082] As time progressed, from 0.5 to 2 hours, the blood glucose concentration in the VC group decreased significantly. From 3 to 8 hours, VC lost its ability to control blood glucose, and the blood glucose concentration was close to that of the M group. At 0.5 hours, the blood glucose concentration level in the AA2G group was comparable to that in the VC and AA-2βG groups (P>0.05). From 2 to 8 hours, the blood glucose concentration in the AA2G group was significantly lower than that in the VC and AA-2βG groups, and the blood glucose concentration in the AA2G group was lower than that in the AA-2βG group at all time points (P<0.05), indicating that the blood glucose lowering effect was AA2G group > AA-2βG group > VC group.

[0083] The serum vitamin C concentration in each group fluctuated significantly over time. At 0.5 h, the AA-2βG and VC groups had the highest serum vitamin C concentrations, while at 2 h, the AA2G group had the highest serum vitamin C concentration. This indicates that AA2G takes longer to break down into vitamin C in the blood than AA-2βG. From 5 to 8 h, the serum vitamin C concentration in the VC group was at a low level and in equilibrium, showing no significant difference from the BC and M groups. The serum vitamin C concentrations in both the AA2G and AA-2βG groups reached their highest values ​​at 5 h, with the AA2G group having a higher concentration than the AA-2βG group, and reached their lowest values ​​at 8 h. In the short term, vitamin C showed the best rapid blood glucose lowering effect, while AA2G and AA-2βG showed the best blood glucose lowering and stabilizing effects. Overall, the blood glucose lowering effect was in the order of AA2G group > AA-2βG group > VC group.

[0084] Comparison of bioactivity after initial administration: The data above indicate that vitamin C (VC) rapidly enters the body at 0.5 h to exert its auxiliary hypoglycemic effect. Due to the relatively stable structures of AA2G and AA-2βG, they cannot be rapidly broken down into VC by glucosidase in the body to exert their hypoglycemic effect. As time increases, VC is gradually broken down due to its active chemical properties, leading to an increase in blood glucose and a decrease in serum VC concentration. However, AA2G and AA-2βG are gradually broken down into VC, thus increasing serum VC concentration and gradually decreasing blood glucose concentration in both groups. The unstable nature of VC prevents it from exerting a long-lasting effect in the body. Compared to AA-2βG, AA2G can more efficiently and stably break down into VC and effectively lower blood glucose concentration. Therefore, AA2G has higher auxiliary hypoglycemic bioactivity than VC and AA-2βG. Within 8 h of administration, the duration of action is AA2G > AA-2βG > VC.

[0085] The effect on blood glucose concentration after 45 days of drug administration is shown in Table 7. Figure 8 As shown:

[0086] Table 7. Comparison of blood glucose concentrations of AA2G, AA-2βG, and VC after 45 days of administration.

[0087]

[0088] Note: P < 0.05 indicates a significant difference, while P ≥ 0.05 indicates no significant difference.

[0089] After 45 days of administration, the blood glucose concentration in the AA2G group was lower than that in the VC group and the AA-2βG group. Combined with the results of the first administration, it can be concluded that AA2G has a sustained and stable effect in lowering blood glucose within 8 hours. Its long-term blood glucose lowering ability is significantly better than that of VC and AA-2βG. AA2G can be used in health foods that can quickly lower blood glucose.

[0090] Example 5

[0091] Methods for evaluating minimum inhibitory concentration (MIC):

[0092] Take 10.0 mL of each sample solution with different dilutions and add it to a petri dish. Add 10 mL of double solid agar medium (45 ℃ water bath) to the petri dish while adding the medium and shaking the dish to mix the sample solution and the medium thoroughly. After solidification, it is ready for use. The medium required for Streptococcus mutans and Porphyromonas gingivalis is double TSA + 10% defatted sheep blood medium.

[0093] The experiment was set up in two parallel operations. 1–2 μL of bacterial suspension (containing approximately 10⁻⁶ bacteria) was taken using a pipette. 7A bacterial colony concentration (CFU / mL) was spotted onto a Petri dish containing the sample solution. The diameter of the resulting bacterial colony ring was approximately 5 mm to 8 mm. The same method was used to inoculate the bacterial colony onto an agar plate without the sample solution as a positive control. Similarly, test tubes without bacterial colony were used as negative controls. All tubes were incubated in a 37 ℃ anaerobic incubator for 24 to 48 hours for observation. The lowest concentration of antibacterial (inhibitory) solution at which colony growth was completely inhibited was defined as the MIC of the sample against the tested bacteria.

[0094] The results are shown in Tables 8 and 9:

[0095] Table 8. Results of the inhibitory inhibitory concentration (MIC) test of AA2G against Streptococcus mutans.

[0096]

[0097] Note: "+" indicates "turbidity with bacteria"; "-" indicates "clear and sterile".

[0098] Table 9. Results of the inhibitory inhibitory (MIC) test of AA2G against Porphyromonas gingivalis.

[0099]

[0100] Note: "+" indicates "turbidity with bacteria"; "-" indicates "clear and sterile".

[0101] The negative control was clear while the positive control was turbid, indicating that the experiment was effective. The MICs of AA2G against Streptococcus mutans and Porphyromonas gingivalis were 1.0% and 2.0%, respectively, indicating that AA2G has an inhibitory effect on these two bacteria.

[0102] Example 6

[0103] Standard qualitative filter paper discs with a diameter of 5 mm were autoclaved, dried, and stored for later use. In a clean bench, a sterilized pipette tip was used to draw up a concentration of 10... 5 ~10 6 CFU / mL bacterial suspension was evenly spread on agar plates to prepare two separate plates (Streptococcus mutans and Porphyromonas gingivalis), which were then dried at room temperature for 5 min. Four sterilized filter paper discs were placed in the center of each plate and marked. 20 μL of AA2G solution was added to three of the filter paper discs, and sterilized physiological saline was added to the remaining disc as a negative control. Another plate was prepared as a positive control, using metronidazole solution, following the same procedure as for the test samples. The plates were inverted and incubated in a 37 ℃ anaerobic incubator for 24 h–48 h for observation, and the diameter of the inhibition zone was measured. Result interpretation: an inhibition zone diameter greater than 7 mm was considered to have antibacterial effect, while an inhibition zone diameter less than or equal to 7 mm was considered to have no antibacterial effect.

[0104] The results are shown in Table 10 and Table 11:

[0105] Table 10. Results of the antibacterial (inhibition zone) experiment of AA2G against Streptococcus mutans.

[0106]

[0107] Table 11. Results of the antibacterial (inhibition zone) experiment of AA2G against Porphyromonas gingivalis.

[0108]

[0109] The inhibition zone experiment results of AA2G against Streptococcus mutans are shown in Table 10. The diameter of the inhibition zone in the negative control group was less than 7 mm, while the diameter in the positive control group was greater than 7 mm, indicating that the experiment was effective. When the concentration of AA2G increased from 5% to 15%, the average diameter of the inhibition zone gradually increased, reaching <7, 7.90, 8.29, 9.11, and 9.72 mm, respectively. Within the concentration range of 7.5% to 15%, the diameter of the inhibition zone was greater than 7 mm, indicating that AA2G exhibited inhibitory effects against Streptococcus mutans within this concentration range.

[0110] The inhibition zone experiment results of AA2G against *Porphyromonas gingivalis* are shown in Table 11. The diameter of the inhibition zone in the negative control group was less than 7 mm, while the diameter in the positive control group was greater than 7 mm, indicating the effectiveness of this experiment. When the concentration of AA2G increased from 6% to 12%, the average diameter of the inhibition zone gradually increased to 8.43, 9.83, 11.66, and 11.67 mm, respectively, with all inhibition zone diameters greater than 7 mm. This indicates that AA2G exhibits inhibitory effects on *Porphyromonas gingivalis* within this concentration range.

[0111] In summary, this invention provides an application of ascorbate glucoside in products that assist in lowering blood sugar, reducing lipids, and preventing dental caries. Specifically, the configuration involved in this invention is 2-O-α-D-glucosyl-L-ascorbic acid (AA2G). AA2G can effectively inhibit α-glucosidase activity and has a high binding rate to bile acids. Animal experiments show that AA2G can significantly reduce blood glucose concentration, serum triglyceride (TG) concentration, and serum total cholesterol (TC) concentration in diabetic model mice, demonstrating its auxiliary effects in lowering blood sugar and lipids. Furthermore, AA2G can significantly inhibit *Streptococcus mutans* and *Porphyromonas gingivalis*, exhibiting anti-caries effects. Moreover, AA2G sustainably and stably exerts its auxiliary effect in lowering blood sugar, with a long-lasting blood sugar-lowering capacity significantly superior to VC and AA-2βG. When applied to health foods and oral care products, AA2G can effectively lower blood sugar and lipids and improve dental caries problems.

[0112] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit them. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments, or make equivalent substitutions for some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions claimed by the present invention.

Claims

1. The application of an ascorbate glucoside in the preparation of health food for assisting in lowering blood sugar and blood lipids, wherein the ascorbate glucoside is 2-O-α-D-glucosyl-L-ascorbic acid; The sole effective ingredient in the health food product used to assist in lowering blood sugar and blood lipids is the 2-O-α-D-glucosyl-L-ascorbic acid. The 2-O-α-D-glucosyl-L-ascorbic acid is used to inhibit α-glucosidase activity and bind to bile acids; the 2-O-α-D-glucosyl-L-ascorbic acid is used to reduce blood glucose concentration, serum triglyceride concentration, and serum total cholesterol concentration, and has the effects of lowering blood glucose and blood lipids.

2. The application according to claim 1, characterized in that, The health food products include beverages, oral liquids, tablets, granules, jelly gels, capsules, or syrups.

Images